30 June 2015
LSE: VER

Vernalis plc announces that Dr Ian David Gilham, aged 55, has been appointed to the Board as a Non-Executive Director with effect from 1 July 2015. Dr Gilham will also serve as Chairman of the Company's Remuneration Committee.

Dr Gilham has international experience in the research, development and commercialisation of diagnostic and pharmaceutical products. He is Non-Executive Chairman of a number of UK and European companies including Epistem Holdings Limited, Concepta Diagnostics Limited, Horizon Discovery Group plc, Multiplicom NV, and Biosurfit SA. Dr Gilham was formerly CEO of Axis-Sheild plc, a FTSE listed global diagnostics company. He also previously worked at GlaxoSmithKline as Vice President – Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

Peter Fellner, Chairman of Vernalis plc, commented:

"I am delighted to welcome Ian to the Vernalis Board. His depth of experience in the global pharmaceutical industry will be very valuable for the Board, and we look forward to his contribution, as we continue to build value for Vernalis' shareholders."

Disclosures:

Dr Gilham is a director or has been a director of the following companies during the previous five years:

Current directorships/partnerships Director/Partner in the last 5 years
Concepta Diagnostics Ltd
Epistem Holdings Plc
Horizon Discovery Group Plc
Multiplicom NV
Biosurfit SA
Stowhealth Ltd
Axis-Shield Plc

Other than as set out above there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Dr Gilham's appointment with effect from 1 July 2015 as a Non-Executive Director of the Company.

-- ends --

 

Enquiries:

Vernalis plc:

 

Ian Garland, Chief Executive Officer

+44 (0) 118 938 0015

David Mackney, Chief Financial Officer

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8350

Dr Julian Feneley

 

Peter Stewart

 

Pippa Underwood

 

Shore Capital (Joint Broker)

+44 (0)20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

Brunswick Group:

+44 (0) 20 7404 5959

Jon Coles

 

 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch